Drug
Calcipotriene And Betamethasone Dipropionate
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Psoriasis | 644 | 32.1 | 39.8 | signal |
| 2 | Psoriatic Arthropathy | 118 | 19.1 | 19.8 | signal |
| 3 | Squamous Cell Carcinoma | 17 | 11.7 | 11.8 | signal |
| 4 | Skin Lesion | 42 | 10.0 | 10.1 | signal |
| 5 | Skin Haemorrhage | 22 | 9.9 | 10.0 | signal |
| 6 | Skin Infection | 17 | 9.9 | 9.9 | signal |
| 7 | Pain Of Skin | 36 | 8.7 | 8.7 | signal |
| 8 | Cellulitis | 66 | 8.5 | 8.7 | signal |
| 9 | Skin Fissures | 24 | 8.3 | 8.3 | signal |
| 10 | Pharyngitis Streptococcal | 13 | 7.8 | 7.8 | signal |
| 11 | Folliculitis | 12 | 7.5 | 7.6 | signal |
| 12 | Oral Candidiasis | 15 | 7.5 | 7.5 | signal |
| 13 | Dermatitis | 23 | 7.2 | 7.3 | signal |
| 14 | Basal Cell Carcinoma | 17 | 7.1 | 7.1 | signal |
| 15 | Scratch | 11 | 6.9 | 6.9 | signal |
| 16 | Skin Disorder | 33 | 6.4 | 6.5 | signal |
| 17 | Malignant Melanoma | 13 | 6.3 | 6.3 | signal |
| 18 | Skin Exfoliation | 70 | 5.5 | 5.6 | signal |
| 19 | Musculoskeletal Chest Pain | 13 | 5.4 | 5.5 | signal |
| 20 | Product Prescribing Error | 18 | 4.9 | 5.0 | signal |
| 21 | Neuralgia | 18 | 4.8 | 4.8 | signal |
| 22 | Synovitis | 13 | 4.7 | 4.7 | signal |
| 23 | Candida Infection | 12 | 4.7 | 4.7 | signal |
| 24 | Hepatocellular Injury | 10 | 4.6 | 4.6 | signal |
| 25 | Localised Infection | 17 | 4.6 | 4.6 | signal |
| 26 | Hepatic Steatosis | 13 | 4.5 | 4.5 | signal |
| 27 | Upper Respiratory Tract Infection | 32 | 4.5 | 4.5 | signal |
| 28 | Ankylosing Spondylitis | 9 | 4.5 | 4.5 | signal |
| 29 | Gastroenteritis | 10 | 4.5 | 4.5 | signal |
| 30 | Sexual Dysfunction | 8 | 4.4 | 4.5 | signal |
| 31 | Tooth Infection | 9 | 4.4 | 4.4 | signal |
| 32 | Inflammation | 35 | 4.4 | 4.5 | signal |
| 33 | Frequent Bowel Movements | 18 | 4.3 | 4.4 | signal |
| 34 | Adrenal Insufficiency | 8 | 4.3 | 4.3 | signal |
| 35 | Hyperlipidaemia | 8 | 4.3 | 4.3 | signal |
| 36 | Nasal Congestion | 39 | 4.3 | 4.4 | signal |
| 37 | Arthritis | 52 | 4.3 | 4.3 | signal |
| 38 | Productive Cough | 31 | 4.2 | 4.3 | signal |
| 39 | Secretion Discharge | 8 | 4.2 | 4.2 | signal |
| 40 | Mass | 9 | 4.2 | 4.2 | signal |
| 41 | Therapy Non-responder | 28 | 4.1 | 4.1 | signal |
| 42 | Therapeutic Product Effect Incomplete | 44 | 4.0 | 4.1 | signal |
| 43 | Lower Respiratory Tract Infection | 28 | 4.0 | 4.0 | signal |
| 44 | Scab | 7 | 4.0 | 4.0 | signal |
| 45 | Ligament Sprain | 6 | 3.9 | 4.0 | signal |
| 46 | Splenomegaly | 7 | 3.9 | 3.9 | signal |
| 47 | Hepatic Cirrhosis | 11 | 3.8 | 3.8 | signal |
| 48 | Liver Function Test Abnormal | 17 | 3.8 | 3.8 | signal |
| 49 | Diverticulitis | 16 | 3.8 | 3.8 | signal |
| 50 | Sinusitis | 59 | 3.7 | 3.8 | signal |
| 51 | Fungal Infection | 19 | 3.7 | 3.7 | signal |
| 52 | Toothache | 10 | 3.6 | 3.6 | signal |
| 53 | Oropharyngeal Pain | 51 | 3.6 | 3.6 | signal |
| 54 | Product Dose Omission | 36 | 3.5 | 3.6 | signal |
| 55 | Dental Caries | 6 | 3.5 | 3.5 | signal |
| 56 | Skin Ulcer | 14 | 3.5 | 3.5 | signal |
| 57 | Appendicitis | 5 | 3.5 | 3.5 | signal |
| 58 | Eczema | 27 | 3.5 | 3.5 | signal |
| 59 | Nasopharyngitis | 98 | 3.4 | 3.5 | signal |
| 60 | Abortion Induced | 5 | 3.4 | 3.4 | signal |
| 61 | Dermatitis Contact | 6 | 3.4 | 3.4 | signal |
| 62 | Ear Infection | 14 | 3.4 | 3.4 | signal |
| 63 | Nephrolithiasis | 24 | 3.4 | 3.4 | signal |
| 64 | Laceration | 5 | 3.4 | 3.4 | signal |
| 65 | Musculoskeletal Discomfort | 9 | 3.4 | 3.4 | signal |
| 66 | Sinus Congestion | 7 | 3.4 | 3.4 | signal |
| 67 | Erythema | 106 | 3.4 | 3.4 | signal |
| 68 | Drug Effect Incomplete | 19 | 3.3 | 3.4 | signal |
| 69 | Vasculitis | 6 | 3.3 | 3.3 | signal |
| 70 | Oral Herpes | 10 | 3.3 | 3.3 | signal |
| 71 | Rash Erythematous | 24 | 3.3 | 3.3 | signal |
| 72 | Decreased Immune Responsiveness | 5 | 3.3 | 3.3 | signal |
| 73 | Cholecystitis | 6 | 3.3 | 3.3 | signal |
| 74 | Abscess | 8 | 3.3 | 3.3 | signal |
| 75 | Oral Pain | 11 | 3.2 | 3.2 | signal |
| 76 | Tooth Abscess | 5 | 3.2 | 3.2 | signal |
| 77 | Rash Macular | 17 | 3.2 | 3.2 | signal |
| 78 | Treatment Failure | 40 | 3.2 | 3.2 | signal |
| 79 | Limb Discomfort | 15 | 3.1 | 3.2 | signal |
| 80 | Cyst | 6 | 3.1 | 3.1 | signal |
| 81 | Hypokinesia | 7 | 3.1 | 3.1 | signal |
| 82 | Dermatitis Allergic | 6 | 3.1 | 3.1 | signal |
| 83 | Muscle Atrophy | 6 | 3.1 | 3.1 | signal |
| 84 | Pruritus | 177 | 3.0 | 3.2 | signal |
| 85 | Skin Cancer | 10 | 3.0 | 3.0 | signal |
| 86 | Ocular Discomfort | 5 | 3.0 | 3.0 | signal |
| 87 | Immune System Disorder | 6 | 3.0 | 3.0 | signal |
| 88 | Pruritus Generalised | 10 | 3.0 | 3.0 | signal |
| 89 | Injection Site Urticaria | 11 | 2.9 | 2.9 | signal |
| 90 | Local Swelling | 8 | 2.9 | 2.9 | signal |
| 91 | Eye Infection | 5 | 2.9 | 2.9 | signal |
| 92 | Stress | 32 | 2.9 | 2.9 | signal |
| 93 | Retinal Detachment | 4 | 2.8 | 2.8 | no signal |
| 94 | Increased Tendency To Bruise | 4 | 2.8 | 2.8 | no signal |
| 95 | Ovarian Cancer | 4 | 2.8 | 2.8 | no signal |
| 96 | Mouth Ulceration | 9 | 2.8 | 2.8 | signal |
| 97 | Skin Reaction | 6 | 2.8 | 2.8 | signal |
| 98 | Cholestasis | 8 | 2.7 | 2.7 | signal |
| 99 | Dry Skin | 55 | 2.7 | 2.7 | signal |
| 100 | Hernia | 8 | 2.7 | 2.7 | signal |
| 101 | Type 2 Diabetes Mellitus | 14 | 2.7 | 2.7 | signal |
| 102 | Application Site Pain | 9 | 2.7 | 2.7 | signal |
| 103 | Injection Site Bruising | 32 | 2.6 | 2.6 | signal |
| 104 | Body Temperature Decreased | 4 | 2.6 | 2.6 | no signal |
| 105 | Intentional Dose Omission | 11 | 2.6 | 2.6 | signal |
| 106 | Joint Swelling | 47 | 2.5 | 2.6 | signal |
| 107 | Injection Site Warmth | 8 | 2.5 | 2.5 | signal |
| 108 | Nodule | 5 | 2.5 | 2.5 | no signal |
| 109 | Bedridden | 5 | 2.5 | 2.5 | no signal |
| 110 | Inappropriate Schedule Of Product Administration | 67 | 2.5 | 2.5 | signal |
| 111 | Respiratory Tract Congestion | 6 | 2.4 | 2.4 | no signal |
| 112 | Renal Cancer | 18 | 2.4 | 2.4 | signal |
| 113 | Uveitis | 5 | 2.4 | 2.4 | no signal |
| 114 | Skin Burning Sensation | 25 | 2.3 | 2.3 | signal |
| 115 | Therapeutic Response Decreased | 21 | 2.3 | 2.3 | signal |
| 116 | Arthropathy | 19 | 2.2 | 2.2 | signal |
| 117 | Therapeutic Product Effect Decreased | 15 | 2.2 | 2.2 | signal |
| 118 | Ischaemic Stroke | 6 | 2.2 | 2.2 | no signal |
| 119 | Drug Effect Decreased | 18 | 2.1 | 2.1 | signal |
| 120 | Brain Neoplasm | 3 | 2.1 | 2.1 | no signal |
| 121 | Tendon Rupture | 4 | 2.1 | 2.1 | no signal |
| 122 | Injection Site Discolouration | 4 | 2.1 | 2.1 | no signal |
| 123 | Therapeutic Response Shortened | 10 | 2.0 | 2.0 | signal |
| 124 | Tuberculosis | 4 | 2.0 | 2.0 | no signal |
| 125 | Knee Operation | 3 | 2.0 | 2.0 | no signal |
| 126 | Maternal Exposure During Pregnancy | 27 | 2.0 | 2.0 | no signal |
| 127 | Application Site Erythema | 8 | 2.0 | 2.0 | no signal |
| 128 | Injection Site Pruritus | 20 | 1.9 | 2.0 | no signal |
| 129 | Sars-cov-2 Test Positive | 4 | 1.9 | 1.9 | no signal |
| 130 | Abortion Spontaneous | 12 | 1.9 | 1.9 | no signal |
| 131 | Hair Texture Abnormal | 4 | 1.9 | 1.9 | no signal |
| 132 | Influenza Like Illness | 24 | 1.9 | 1.9 | no signal |
| 133 | Injection Site Swelling | 22 | 1.9 | 1.9 | no signal |
| 134 | Acne | 22 | 1.9 | 1.9 | no signal |
| 135 | Prostatic Specific Antigen Increased | 4 | 1.9 | 1.9 | no signal |
| 136 | Drug Effect Less Than Expected | 4 | 1.8 | 1.8 | no signal |
| 137 | Injection Site Erythema | 35 | 1.8 | 1.8 | no signal |
| 138 | Inappropriate Schedule Of Drug Administration | 20 | 1.8 | 1.8 | no signal |
| 139 | Anosmia | 4 | 1.8 | 1.8 | no signal |
| 140 | Pancreatic Carcinoma | 8 | 1.8 | 1.8 | no signal |
| 141 | Drug Dose Omission | 44 | 1.7 | 1.7 | no signal |
| 142 | Dermatitis Atopic | 13 | 1.7 | 1.7 | no signal |
| 143 | Injection Site Pain | 78 | 1.7 | 1.7 | no signal |
| 144 | Sleep Disorder Due To A General Medical Condition | 4 | 1.6 | 1.6 | no signal |
| 145 | Bone Marrow Failure | 5 | 1.6 | 1.6 | no signal |
| 146 | Skin Irritation | 11 | 1.6 | 1.6 | no signal |
| 147 | Hair Colour Changes | 3 | 1.5 | 1.5 | no signal |
| 148 | Incorrect Dose Administered By Device | 6 | 1.5 | 1.5 | no signal |
| 149 | Injection Site Induration | 3 | 1.5 | 1.5 | no signal |
| 150 | Injection Site Haemorrhage | 18 | 1.5 | 1.5 | no signal |
| 151 | Injection Site Reaction | 15 | 1.4 | 1.4 | no signal |
| 152 | Pregnancy | 4 | 1.3 | 1.3 | no signal |
| 153 | Incorrect Product Administration Duration | 4 | 1.3 | 1.3 | no signal |
| 154 | Breast Cancer | 18 | 1.2 | 1.2 | no signal |
| 155 | Premature Delivery | 3 | 1.2 | 1.2 | no signal |
| 156 | Needle Issue | 5 | 1.1 | 1.1 | no signal |
| 157 | Oesophageal Carcinoma | 5 | 1.1 | 1.1 | no signal |
| 158 | Injection Site Rash | 5 | 1.1 | 1.1 | no signal |
| 159 | Suicide Attempt | 10 | 1.1 | 1.1 | no signal |
| 160 | Device Malfunction | 11 | 1.1 | 1.1 | no signal |
| 161 | Menorrhagia | 3 | 1.0 | 1.0 | no signal |
| 162 | Device Issue | 13 | 1.0 | 1.0 | no signal |
| 163 | Prostate Cancer | 12 | 1.0 | 1.0 | no signal |
| 164 | Wrong Technique In Drug Usage Process | 5 | 0.9 | 0.9 | no signal |
| 165 | Injection Site Mass | 5 | 0.9 | 0.9 | no signal |
| 166 | Dependence | 7 | 0.8 | 0.8 | no signal |
| 167 | Hepatic Cancer | 3 | 0.8 | 0.8 | no signal |
| 168 | Menstruation Irregular | 3 | 0.7 | 0.7 | no signal |
| 169 | Drug Exposure During Pregnancy | 3 | 0.6 | 0.6 | no signal |
| 170 | Incorrect Route Of Drug Administration | 3 | 0.5 | 0.5 | no signal |
| 171 | Device Breakage | 3 | 0.5 | 0.5 | no signal |
| 172 | Wrong Technique In Device Usage Process | 3 | 0.4 | 0.4 | no signal |